Fortis AI-Powered Hybrid Cath Lab Opens in New Delhi

The Fortis AI-powered hybrid cath lab in New Delhi is the latest sign of hospitals investing in imaging-led heart care. In a press release published on 13 October 2026, Fortis Healthcare said Fortis Escorts, New Delhi has installed the ARTIS pheno.vision, which it describes as an AI-powered, robot-assisted hybrid catheterisation laboratory combining robotic angiography, AI-assisted imaging and hybrid operating-room capabilities. It is designed for complex heart and vascular procedures, including minimally invasive ones.

This is an announcement of equipment, not a study. The hospital says the setup may improve precision and lower radiation, but it published no patient outcomes, radiation measurements or procedure volumes. Here is what the system is, what the hospital says it does, what the evidence gap looks like and why it matters for hospital technology in India.

Fortis AI-powered hybrid cath lab: what was announced

• What: the ARTIS pheno.vision hybrid cath lab, combining robotic angiography, AI-powered imaging, 3D visualisation and hybrid operating-room features.
• Where: Fortis Escorts, New Delhi.
• Purpose: help teams plan procedures, acquire images and navigate devices, and allow catheter-based and surgical care to be coordinated in one room when clinically needed.
• Exclusivity claim: Dr Ashok Seth, Chairman of Cardiac Sciences at Fortis Healthcare, said Fortis Escorts is the only corporate hospital to have integrated this technology. That is the hospital’s statement and we could not verify it.
• Not disclosed: cost, the number of cases performed, radiation figures, and the manufacturer, which the hospital materials we saw did not name.

What the Fortis AI-powered hybrid cath lab actually is

A catheterisation lab is a room where doctors guide thin tubes, called catheters, through blood vessels to the heart or elsewhere, using live X-ray images. A hybrid lab adds the sterile conditions, space and equipment of an operating theatre, so that if a catheter procedure needs to become open surgery, the team does not have to move the patient to another room. This matters for high-risk patients, since transfers take time and carry risk.

Adding robotics means the imaging equipment can be positioned by motorised arms to reach set positions around the patient, and adding AI generally means software that helps with tasks such as image processing and guidance. The hospital’s materials did not describe exactly which tasks are AI-driven.

Procedures the Fortis AI-powered hybrid cath lab is built for

• Endovascular repair of aortic aneurysms and complex aortic repairs.
• Transcatheter aortic valve implantation (TAVI), a way to replace a narrowed valve without open-heart surgery.
• Mitral valve repair and transcatheter replacement, including clip-based repair.
• Image-guided treatment of peripheral vascular disease.
• Implantation of pacing devices, including cardiac resynchronisation defibrillators and leadless pacemakers.
• Selected procedures that combine robotic cardiac surgery with angioplasty.

The ARTIS pheno platform

ARTIS pheno is a Siemens Healthineers angiography system, according to the manufacturer’s product page. The manufacturer describes it as designed for planning, guidance during procedures and immediate assessment, for use in an interventional suite or hybrid operating room, with a wide-space C-arm, a flexible isocenter and support for third-party surgical tables. It lists procedures such as TAVI and fenestrated aortic repair, and claims potentially less radiation and contrast in TAVI. These are manufacturer claims.

The “pheno.vision” name used in the hospital’s release does not appear on the product page we reviewed, so we cannot say which AI features the Delhi installation includes beyond the hospital’s general description. Readers should ask the hospital for specifics.

The Fortis AI-powered hybrid cath lab claims, and the evidence gap

The hospital says the approach may offer sharper imaging, more accurate device placement, and a lower radiation dose, as Dr Seth put it. For suitable patients it says the technology may reduce the need for open surgery, procedural trauma, hospital stay and recovery time, and may lower the risk of complications such as infection, depending on the procedure, the patient and the complexity of the case. These statements are conditional, and the release gives no data.

Radiation is a real consideration in X-ray guided procedures, where doctors balance image quality against dose; the US Food and Drug Administration explains how fluoroscopy works and why dose is managed. But a feature that can lower dose does not guarantee a lower dose in practice, which depends on how the system is set up and used. Better outcomes need to be shown in comparisons of patients treated with and without the technology, which is not what this announcement provides.

Market context

Hospitals buying advanced angiography systems are part of a large global market. Acumen Research and Consulting values the global angiography devices market at USD 12.9 billion in 2023 and forecasts USD 22.0 billion by 2032, a compound annual growth rate of 6.2%, and expects Asia-Pacific to grow rapidly with favourable government regulation in India, China and Japan. That market covers more than imaging systems, including catheters, contrast media, guidewires and vascular closure devices, so it is not a measure of what hospitals spend on equipment like this. Market forecasts are projections, not measurements.

Why the Fortis AI-powered hybrid cath lab matters for India

Cardiovascular disease is the leading cause of death worldwide, according to the World Health Organization, and India’s large private hospitals compete partly on the technology they can offer for complex cases. A hybrid lab makes it possible to treat patients with several problems in one setting, which could draw patients who would otherwise travel abroad. It also raises questions about cost and access, since the hospital gave no pricing and advanced systems usually concentrate in major cities.

Our assessment of the Fortis AI-powered hybrid cath lab

In our assessment, the Fortis AI-powered hybrid cath lab is a meaningful infrastructure investment, but a hospital’s equipment is not evidence of better care. The most credible near-term benefit is logistical: having catheter and surgical capability in one room can save time in complex cases. Claims about lower radiation, greater precision and better recovery should be treated as plausible but unproven until the hospital publishes dose measurements and outcomes for its own patients. For related coverage, see our reports on physical AI in healthcare, the AI-assisted surgery market and the Hēlo thrombectomy clearance, or browse our medical device coverage.

What to watch next

• Published case numbers and outcomes from the new lab.
• Radiation dose and contrast data compared with the hospital’s earlier cath labs.
• Details of the AI features, and the manufacturer’s regulatory status for them in India.
• Similar installations at other Indian hospitals.

Frequently asked questions

What is the Fortis AI-powered hybrid cath lab?

An AI-powered, robot-assisted hybrid catheterisation laboratory, the ARTIS pheno.vision, at Fortis Escorts, New Delhi, combining robotic angiography, AI-assisted imaging and operating-room capabilities.

What procedures can the Fortis AI-powered hybrid cath lab support?

The hospital lists aortic repairs, TAVI, mitral procedures, peripheral vascular interventions and device implants such as leadless pacemakers.

Does the Fortis AI-powered hybrid cath lab improve patient outcomes?

The announcement does not establish that. It gives no outcome data.

Does it reduce radiation?

The hospital says a lower dose will help, but it gave no figures.

Is it the only one in India?

The hospital says it is the only corporate hospital to have integrated this technology; we could not verify the claim.

How we reported this: we relied on the hospital’s press release of 13 October 2026, the manufacturer’s public product page and a market-research report, as linked above. We did not visit the facility. Last updated: 13 October 2026. This article is news reporting and not medical advice.